收藏切换
Progress in the implementation of conditional approval process for drugs in China: a pooled analysis from 2020 to 2024
收藏切换
Li WANG, Xiang-qi ZHAO, Gui-yu LIAN*, Zhe HUANG*
Chinese Journal of New Drugs | 2026, 35(13) : 1372 - 1377
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(13): 1372-1377
Progress in the implementation of conditional approval process for drugs in China: a pooled analysis from 2020 to 2024
Full
Li WANG, Xiang-qi ZHAO, Gui-yu LIAN*, Zhe HUANG*
Affiliations
  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China
Published: 2026-07-15 doi: 10.20251/j.cnki.1003-3734.2026.13.005
Outline
收藏切换
Objective:

To conduct a comprehensive analysis of drugs marketed through the conditional approval process in China from 2020 to 2024, along with recommendations for improving this process.

Methods:

Drugs conditionally approved during the study period were identified through the National Medical Products Administration public data, the Center for Drug Evaluation public data, and the Yaozhi Database. The basic information, pre-market clinical trial studies, and post-marketing study requirements and progress were collected and analyzed.

Results:

A total of 143 approved matters were marketed through the conditional approval process. Key characteristics included: R&D resources were highly concentrated on antineoplastic drugs, a high percentage of applications in pre-market pivotal clinical trials were based on surrogate endpoints, and the conversion rate of drugs from conditional approval to full approval was low.

Conclusion:

It is necessary to strengthen the guidance provided by drug regulatory and relevant departments, establish a system for recognizing surrogate endpoints, and improve the flexibility of the conditional approval process.

conditional approval  /  approved drug  /  basic information  /  clinical trials  /  post-marketing study
王莉, 赵祥琦, 连桂玉, 黄哲. 我国药品附条件批准程序实施进展:2020—2024年汇总分析. 中国新药杂志, 2026 , 35 (13) : 1372 -1377 . DOI: 10.20251/j.cnki.1003-3734.2026.13.005
Li WANG, Xiang-qi ZHAO, Gui-yu LIAN, Zhe HUANG. Progress in the implementation of conditional approval process for drugs in China: a pooled analysis from 2020 to 2024[J]. Chinese Journal of New Drugs, 2026 , 35 (13) : 1372 -1377 . DOI: 10.20251/j.cnki.1003-3734.2026.13.005
Year 2026 volume 35 Issue 13
48
12
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.13.005
  • Online Date:2026-10-26
  • Published:2026-07-15
Article Data
Affiliations
History
  • Accepted:2025-10-15
Affiliations
    School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.13.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT